TACROLIMUS GENOTYPING (CYP3A5) / EDTA BLOOD

image not found

NABL Cap Accredited      
This test analyzes CYP3A5 gene variants that influence how a patient metabolizes tacrolimus, an important immunosuppressant used after organ transplantation. Understanding a patient’s genetic profile helps clinicians determine optimal dosing and reduce the risk of toxicity or graft rejection. It is especially valuable for personalized medicine and treatment monitoring. Metropolis Healthcare offers precise and reliable genotyping to support safe and effective tacrolimus therapy

  • 17 Crores+ Samples Processed
  • World Class Technology Labs
  • 25+ Years of Trust & Experience
  • Free Home Collection

Price: Rs. 8,400.00

Sample Type: EDTA BLOOD

Fasting Not Required


Notes: T0080

Frequently Asked Questions (FAQ's):

What does the Tacrolimus Genotyping (CYP3A5) test check at Metropolis Healthcare?
It identifies CYP3A5 genetic variants that affect how the body processes tacrolimus.

Why is CYP3A5 genotyping important for tacrolimus therapy?
It helps predict whether a patient is a fast or slow metabolizer, guiding dose adjustments.

How does Metropolis Healthcare perform this test?
EDTA blood samples are analyzed using advanced molecular techniques for accurate genotyping.

Who should undergo this test?
Patients receiving tacrolimus after organ transplant or those with unstable tacrolimus levels.

Does this test help prevent side effects?
Yes, by guiding dosing, it helps reduce risks like nephrotoxicity and under-immunosuppression.

Is fasting required for the test?
No, fasting or special preparation is not needed.

Can genotyping replace tacrolimus level monitoring?
No, it complements drug level monitoring to optimize therapy.

How does this test support personalized medicine at Metropolis Healthcare?
It enables tailored dosing based on an individual’s genetic makeup for safer treatment outcomes.

OUR corporates PARTNER

Feedback

Patient's Testimonials

Trusted by Thousands

OUR Accreditations

OUR Lab